title: Effects of phytosterols in diacylglycerol as part of diet therapy on hyperlipidemia in children.
abstract: BACKGROUND
  The incidence of hyperlipidemia in children is increasing in Japan, but drug therapy for such children is limited. The ingestion of 4% phytosterols-containing diacylglycerol (PS/DAG) decreases serum total cholesterol and low density lipoprotein cholesterol (LDL-C) concentrations in adults. In the present study, we examined the effect of PS/DAG as part of a diet therapy in pediatric patients with hyperlipidemia.
  
  
  METHODS
  Pediatric patients with hyperlipidemia with > or =5.18mmol (200 mg/dL) serum total cholesterol and/or >or =1.70mmol (150 mg/dL) triglycerides (N=22) ingested bread containing PS/DAG (total daily intake, 10g) for 6 months. Blood chemistry was examined prior to and 2, 4, 6 months after the initiation of ingestion, and 4 months after the ingestion period.
  
  
  RESULTS
  No significant differences in energy intake or cholesterol intake during the study period were found. After 4 months of ingestion of PS/DAG, LDL-C, lipoprotein(a) [ Lp(a)], free fatty acids and total ketone bodies decreased significantly. In seven patients with familial hypercholesterolemia, total cholesterol and remnant-like lipoprotein particles (RLP)-cholesterol also significantly decreased in addition to LDL-C and Lp(a).
  
  
  CONCLUSIONS
  PS/DAG improves serum lipid metabolism in pediatric patients with hyperlipidemia for whom drug therapy is limited, suggesting that PS/DAG may reduce the risk of developing various diseases induced by hyperlipidemia.
authors.affiliation: Department of Pediatrics, Fussa Hospital, 1-6-1 Kamidaira, Fussa-shi, Tokyo 197-8511, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Kentaro
authors.initials: K
authors.lastname: Shoji
authors.forename: Hideto
authors.initials: H
authors.lastname: Takase
authors.forename: Isamu
authors.initials: I
authors.lastname: Kamimaki
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Atsuko
authors.initials: A
authors.lastname: Otsuka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hase
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tokimitsu
mesh_terms: D000293:Adolescent; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004075:Diglycerides / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy*; D008297:Male; D010840:Phytosterols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004075:Diglycerides; D010840:Phytosterols; D002784:Cholesterol